Evidence map›Paper›PMID 40360003›Full record

ReviewArquivos de neuro-psiquiatria2025

A decade of whole-exome sequencing in Brazilian Neurology: from past insights to future perspectives.

Caio Robledo D'Angioli Costa Quaio, Thiago Yoshinaga Tonholo Silva, Orlando G Barsottini, Sarah Teixeira Camargos, Marcondes C França, Jonas A Saute, Wilson Marques, Fernando Kok, José Luiz Pedroso

Abstract readReview
In one paragraph

Review in Arquivos de neuro-psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genomic landscape of autism spectrum disorder in Brazil.Genetics and molecular biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Caio Robledo D'Angioli Costa QuaioHospital Israelita Albert Einstein, São Paulo SP, Brazil.ORCID 0000-0003-2873-2820
Thiago Yoshinaga Tonholo SilvaHospital Israelita Albert Einstein, São Paulo SP, Brazil.ORCID 0000-0002-7185-8309
Orlando G BarsottiniHospital Israelita Albert Einstein, São Paulo SP, Brazil.ORCID 0000-0002-0107-0831
Sarah Teixeira CamargosUniversidade Federal de Minas Gerais, Belo Horizonte MG, Brazil.ORCID 0000-0001-9829-6783
Marcondes C FrançaUniversidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Neurologia, Campinas SP, Brazil.ORCID 0000-0003-0898-2419
Jonas A SauteUniversidade Federal do Rio Grande do Sul, Faculdade de Medicina, Departamento de Medicina Interna, Porto Alegre RS, Brazil.ORCID 0000-0003-1141-6573
Wilson MarquesUniversidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Neurociências e Ciências do Comportamento, Ribeirão Preto SP, Brazil.ORCID 0000-0002-4589-2749
Fernando KokMendelics Análise Genômica, São Paulo SP, Brazil.ORCID 0000-0002-7577-9122
José Luiz PedrosoHospital Israelita Albert Einstein, São Paulo SP, Brazil.ORCID 0000-0002-1672-8894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last decade, whole-exome sequencing (WES) has become a standard diagnostic tool, significantly transforming the landscape of clinical genetics and playing a pivotal role in the diagnosis of neurogenetic diseases. This revolutionary shift has left a lasting impact on the field of neurology in Brazil. The current review article examines key developments and milestones achieved in Brazil through the application of WES in neurology and discusses forthcoming challenges and essential steps to advance molecular diagnosis. Several studies report the use of WES to diagnose genetic disorders with neurological manifestations in Brazil, underscoring the growing importance of molecular diagnosis in neurogenetics. These studies often provide detailed phenotypic analyses and clinical descriptions, offering valuable insights into the genetic underpinnings of several neurological conditions. Many reports highlight the use of WES in the investigation of complex neurological conditions in Brazil, such as neurodevelopmental disorders, hereditary spastic paraplegia, movement disorders, and ataxia. The discovery of new genes implicated in monogenic diseases with neurological manifestations through WES was a significant breakthrough. Despite these advances, the availability of large cohort studies on rare diseases in Brazil remains limited, hindering the ability to generalize findings and explore the full spectrum of genetic diversity. However, a few larger cohort studies have substantially contributed to our understanding of rare diseases and specific neurological disorders.While WES has limitations and may eventually be supplanted by more advanced diagnostic tools, it left a permanent mark on the neurology field in Brazil. The field of neurogenetics is set to become increasingly important in the future.

Indexed as

Exome SequencingNervous System DiseasesNeurologyBrazilHumans

Identifiers

PMID40360003
PMCPMC12074826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.